HMS in the News
Recent Releases
Breakthrough Cures, Blockbuster Costs: Future Directions
Health, Medicine & Society
Published by Blue Cross Blue Shield Association and HMS, this report examines advanced therapies—biomedical breakthroughs that often treat rare conditions and can transform or even save a patient’s life—that tend to come with extremely high price tags. By 2031, as many as 90 gene and cellular therapies are expected to be approved for use by 550,000 patients, at an annual acquisition cost of $30 billion. A framework for ensuring that high-cost medicines for rare conditions are affordable and accessible to patients emerged from a convening co-chaired by two former U.S. Food and Drug Administration (FDA) commissioners, Scott Gottlieb and Margaret Hamburg.
